कंपनी का अवलोकन
IM Cannabis Corp. (IMCC) operates within the healthcare sector, specifically functioning as a drug manufacturer focused on specialty and generic pharmaceuticals. The company's core business involves the breeding, cultivation, and supply of medical cannabis products, offering dried flowers and various extracts under its portfolio of brands including IMC, BLKMT, WAGNERS, and LOT420. These products are primarily distributed to serve medical patients in key markets such as Israel and Germany. As of the latest data, the enterprise carries a market capitalization of $2.21M and generated annual revenue of $54.73M over the trailing twelve months. The absence of specific employee count data limits the ability to gauge headcount efficiency, yet the revenue figure relative to the small market cap suggests the company operates with a lean or unlisted workforce structure. This valuation indicates a micro-cap position where the revenue base is substantial relative to the equity value, often seen in early-stage or turnaround biotechnology and specialty manufacturing firms. The company was founded in 200, establishing a long operational history within the regulated cannabis landscape despite its current small market valuation.
वित्तीय स्वास्थ्य
The company reported a total revenue of $54.73M for the trailing twelve months, yet it recorded a net income of $-11,319,000 and an EBITDA of $-4,559,000. The significant disparity between the positive revenue and the negative net income reveals a heavy cost structure where operating expenses and cost of goods sold consume the majority of top-line sales before reaching the bottom line. Specifically, the operating margin of -31.4% and profit margin of -20.7% highlight that for every dollar of sales, the company retains less than twenty cents in profit after all costs, while the negative EBITDA of $-4,559,000 underscores the high cash burn rate inherent in the cultivation and manufacturing process. The free cash flow stands at $-431,875, indicating a continuous outflow of cash that constrains financial flexibility and necessitates external financing or internal cash reserves to sustain operations. On the liquidity front, the company holds $2.73M in cash against $16.27M in debt, creating a negative net cash position that implies a leveraged balance sheet rather than a conservative one. Although the debt-to-equity ratio is listed as N/A, the sheer magnitude of debt relative to cash reserves suggests significant leverage risk. Furthermore, the current ratio of 0.67 indicates that current liabilities exceed current assets, signaling potential challenges in meeting short-term obligations without refinancing or asset liquidation. Finally, with Return on Equity and Return on Assets both listed as N/A or negative (ROA at -10.9%), these return metrics reveal that management is currently destroying shareholder value rather than generating efficient returns on deployed capital.
मूल्यांकन आकलन
Valuation metrics for IM Cannabis Corp. present a complex picture due to the lack of profitability, with the trailing P/E ratio listed as N/A and the forward P/E standing at -0.27. The negative forward P/E implies that the market is pricing in expected losses rather than earnings growth, which is typical for pre-profitability biotech or specialty manufacturing stocks. The price-to-book ratio is -0.78, indicating that the market values the company at less than its net book value, a scenario often driven by accumulated losses that reduce shareholders' equity below zero. Additionally, the price-to-sales ratio of 0.04 and EV/EBITDA of -3.48 suggest that the market is not applying a standard multiple to sales or earnings, effectively pricing the stock based on asset liquidation value or speculative upside. Regarding price action, the 52-week high was $7.12 while the 52-week low was $0.29, meaning the stock has experienced extreme volatility within this range. Without a specific current price to calculate the exact percentage, the valuation context is defined by this wide spread, suggesting the stock is sensitive to regulatory news or clinical trial results that could trigger sharp re-pricing. The beta value of 2.27 indicates that the stock's price volatility is more than twice that of the broader market, reflecting high sensitivity to sector-specific risks and investor sentiment. These alternative valuation metrics collectively suggest that traditional earnings-based valuation models are not applicable, and investors must rely on asset-based or scenario-based analysis to assess the company's worth.
Growth & Income
The company demonstrated revenue growth of 17.6% year-over-year, while the earnings growth rate is listed as N/A due to the company's current net loss position. The divergence between growing revenue and absent earnings growth implies that top-line expansion is occurring, but the underlying cost structure has not yet achieved the profitability required to translate sales increases into net income. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all available earnings—or rather, all available cash flows—back into the business to fund operations and growth initiatives. This reinvestment approach is typical for companies in the drug manufacturing sector that are still navigating the path to commercial profitability and regulatory compliance in international markets. The overall growth and income profile reflects a high-risk, high-reward trajectory where capital appreciation is the sole source of return for shareholders, with no income support from dividends. The absence of a dividend stream confirms that the company prioritizes operational scaling and product development over returning capital to investors during this development phase.